INTRODUCTION
============

HIV-related renal diseases are one of the leading causes of chronic kidney diseases (CKDs) worldwide. In particular, the new era of highly active antiretroviral therapy (HAART) and early HIV diagnosis has improved survival and disease progression, leading to a higher proportion of patients with renal abnormalities over time [@b1-cln_70p691]-[@b3-cln_70p691].

CKD is defined by a sustained change in urinary sediment, such as the presence of proteinuria, or by a reduced glomerular filtration rate (GFR). Proteinuria is often the earliest manifestation of CKD and is more common in HIV-infected individuals than in similarly aged HIV-negative controls [@b1-cln_70p691],[@b4-cln_70p691],[@b5-cln_70p691]. Risk factors for incident or progressive CKD in HIV-positive adults include apolipoprotein-1 genetic polymorphism [@b4-cln_70p691], hepatitis C virus (HCV) coinfection [@b5-cln_70p691], a low CD4 T-cell count, a high HIV viral load and traditional CKD risk factors such as diabetes and hypertension [@b6-cln_70p691].

The present study aimed to investigate the prevalence of pathological proteinuria and its risk factors among HIV patients from a public HIV/AIDS reference clinic in Porto Alegre, Brazil.

MATERIALS AND METHODS
=====================

The present research was a cross-sectional study of HIV-infected patients who attended a public HIV/AIDS clinic in Porto Alegre, Brazil. The data were collected from the records of patients who attended between March 2008 and December 2012. The study population included HIV patients aged 18 years or older who were from the city of Porto Alegre and surrounding metropolitan region. All participants had free access to health care and medications, in line with the national health program. Cases were excluded if records were not available for analysis.

Data collected from records included age, gender, ethnicity, body mass index (BMI), smoking history, use of illicit drugs and alcohol, previous diagnosis of hypertension, diabetes mellitus, chronic hepatitis B infection, chronic HCV infection, lipid levels, glucose levels, urinalysis results, arterial hypertension, drugs being used, current CD4 count (cells/mm^3^), current plasma HIV RNA level (viral load), absence (*naïve*) or use of HAART and type of HAART under use.

Urine samples were analyzed by the Department of Laboratory Medicine at the Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil and the diagnosis of proteinuria was made based on the urinary protein-to-creatinine ratio (PCR) in a single-spot urine analysis [@b3-cln_70p691]. Overt proteinuria was defined as a PCR greater than 150 mg/g according to Kidney Disease: Improving Global Outcomes (KDIGO) [@b7-cln_70p691].

Blood pressure was determined based on an average of two measurements using a calibrated automated machine, with each participant sitting in a relaxed, upright position. Hypertension was defined according to standard definitions set out in the Eighth Joint National Committee guidelines [@b8-cln_70p691]. Patients receiving an antihypertensive medication, irrespective of blood pressure, were also defined as hypertensive [@b8-cln_70p691]. The criteria for the definitions of diabetes and dyslipidemia followed ADA [@b9-cln_70p691] and AACE [@b10-cln_70p691] guidelines.

Statistical analyses included descriptive statistics with numbers (proportions) for categorical variables and means (± standard deviation) for continuous variables. Categorical variables were assessed using the chi-square test or Fisher\'s exact test and quantitative variables were compared using Student\'s t-test. Adjusted residual analysis was performed to detect categories with a two-tailed (higher or lower) expected frequency.

Significant variables with *p*\<0.20 in the univariate analysis were further analyzed using a Poisson regression model with robust variance. Fosamprenavir plus ritonavir (FPV/r) treatment was not included in this model due to its use by only a small number of patients. A value of *p*\<0.05 was considered statistically significant. All statistical analyses were performed using the SPSS software, version 18 (IBM, Armonk, NY, USA).

Ethics
------

The present research was approved by the Ethics Committee of the Municipal Council of Health of Porto Alegre city, under protocol number 05773912.1.0000.5338, in January 2013.

RESULTS
=======

Demographics
------------

Initially, 744 HIV-infected individuals were identified, but 78 were excluded due to a lack of complete medical records. Therefore, the medical records of 666 HIV-infected individuals aged 18 years or older in an urban HIV/AIDS clinic based in Porto Alegre in southern Brazil were ultimately evaluated. The mean age of the group was 42.02±11.8 years and 51.5% were male. Moreover, 60.7% of the individuals were Caucasian and 39.3% were Black. Diabetes mellitus was present in only 5.9% of the study population, whereas dyslipidemia was present in 26.2%. A smoking habit was present in 39.3%, and 13.7% of evaluated patients had a BMI higher than 30 kg/m^2^. In terms of the CD4 count, 10.5% had a current count \<200 cells/mm^3^; 42.4%, between 200 and 500 cells/mm^3^; and 47.1%, \>500 cells/mm^3^. In total, 60% had an undetectable viral load (\<50 copies/mL) and 77.7% were currently receiving HAART. Finally, only two patients had serum creatinine greater than 1.5 mg/dL. The group demographic values are presented in [Table 1.](#t1-cln_70p691){ref-type="table"} The prevalence of hypertension in this study cohort was 22.5% (227 individuals). A total of 150 patients were taking antihypertensive drugs. More specifically, 77 individuals (51.33%) were taking only one antihypertensive, 50 (33.33%) were taking two and 23 (15.33%) were taking a combination of three or more drugs. The most common antihypertensive medications were angiotensin-converting enzyme inhibitors (n=100), diuretics (n=61), beta-blockers (n=47), angiotensin II receptor antagonists (n=20) and calcium channel blockers (n=12). In contrast, in the studied group, 61 (40.66%) individuals did not have controlled blood pressure, despite antihypertensive therapy.

Characteristics associated with pathological proteinuria
--------------------------------------------------------

The prevalence of pathological proteinuria in the present study cohort was 20% (95% CI: 16.9% to 23.0%), with no difference observed between the groups receiving HAART (19.2%) and not receiving HAART (20.7%) (*p*=0.773). The mean ages of the individuals in the pathological proteinuria group and the non-pathological proteinuria group were 45.8±12.7 years and 41.1±11.4 years, respectively (*p*=0.003). Characteristics associated with pathological proteinuria after univariate analysis included alcohol abuse (*p=*0.019), HCV coinfection (*p*\<0.001) and the occurrence of diabetes (*p*=0.006). Therapy including tenofovir among individuals under HAART presented a similar association (*p*\<0.001). Adjusted residuals analysis indicated an association between pathological proteinuria and both a CD4 lymphocyte count below 200 cells/mm^3^ (*p*\<0.001) and viral load higher than 1000 copies/mL (*p*=0.026). Additionally, an absence of pathological proteinuria was associated with a CD4 lymphocyte count higher than 500 cells/mm^3^ (*p*\<0.001).

When the individuals under tenofovir therapy were evaluated regarding proteinuria, 30.11% (53/176) patients had pathological proteinuria and only 20.75% (11/53) of these individuals had albuminuria detected by dipstick.

After adjustment for all variables with *p*\<0.2 in the univariate analysis using a Poisson regression model, tenofovir-containing regimens and a CD4 lymphocyte count below 200 cells/mm^3^ were significantly associated with pathological proteinuria. Additionally, within this setting, a viral load higher than 1,000 copies/mL (*p*=0.065) showed a tendency toward association with pathological proteinuria. The regression model values are shown in [Table 2.](#t2-cln_70p691){ref-type="table"}

DISCUSSION
==========

Proteinuria is part of the definition of CKD and is a risk marker for progression to end-stage renal disease (ESRD). HIV-associated nephropathy (HIVAN)-related risk factors, including an elevated HIV RNA level, a low absolute CD4 lymphocyte count, apolipoprotein-1 genetic polymorphism and hepatitis C and hepatitis B coinfection, are associated with proteinuria [@b2-cln_70p691]. The present study detected a high prevalence of pathological proteinuria (20%) among HIV-infected individuals, similar to other studies in the literature, which have reported prevalence values ranging from 17% to 32% [@b1-cln_70p691],[@b11-cln_70p691].

This study examined the factors associated with proteinuria within a large cohort of HIV-infected patients. Proteinuria was specifically associated with an elevated HIV RNA level and a CD4 lymphocyte count below 200 cells/mm^3^. These findings are consistent with prior studies, in which risk factors for incident or progressive CKD in HIV-positive adults included HIV disease severity [@b1-cln_70p691],[@b7-cln_70p691],. However, factors traditionally associated with CKD that have been described in the literature, such as age, cardiovascular disease [@b1-cln_70p691],[@b4-cln_70p691], diabetes, hypertension, obesity [@b6-cln_70p691],[@b12-cln_70p691] and HCV [@b13-cln_70p691], were not linked to pathological proteinuria among HIV-positive individuals in the current study after multivariate analysis.

The relationship between antiretrovirals and pathological proteinuria was also examined and tenofovir-based therapy was significantly associated with this condition in the multivariate analysis. Most of the individuals in this group who presented with pathological proteinuria did not have albuminuria detected by dipstick (79.25%), suggesting proteinuria of tubular origin. Thus, these patients would not have benefited from using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Meanwhile, FPV/r therapy showed a tendency toward association with pathological proteinuria. However, due to the small number of patients, fosamprenavir was not included in the multivariate analysis. All other antiretrovirals were not linked to pathological proteinuria.

Patients with HIV infection are at risk of developing nephrotoxicity in response to antiretrovirals. In fact, tenofovir and boosted protease inhibitors have been associated with a decline in the GFR [@b14-cln_70p691],[@b15-cln_70p691]. Tenofovir is specifically a nucleoside reverse transcriptase inhibitor that can cause acute kidney injury (AKI), proximal tubular dysfunction, or both in combination. The risk of kidney toxicity with tenofovir has varied across different studies, with estimates ranging from 2% to 10% [@b15-cln_70p691],[@b16-cln_70p691].

The benefits of antiretrovirals concerning proteinuria may be less substantial with regimens containing tenofovir compared with the alternative, namely, nucleoside reverse transcriptase inhibitors [@b17-cln_70p691]. Although a kidney biopsy may not be necessary to diagnose tenofovir toxicity, it can be useful in cases where the diagnosis is less clear or where there are compelling reasons not to discontinue tenofovir [@b18-cln_70p691]. In addition, in the setting of renal disease, a regimen containing a boosted protease inhibitor (such as FPV/r) in combination with tenofovir has been associated with a decrease in the GFR [@b14-cln_70p691],[@b19-cln_70p691].

The present study has certain limitations. For example, several of our findings could have been underestimated, given that the durations of HIV disease and HAART were not evaluated. Additionally, our analyses were based on a cross-sectional study; hence, the temporality between factors and the development of pathological proteinuria could not be established. It was also difficult to estimate the number of patients with CKD due to the small proportion of patients with abnormal serum creatinine.

Conversely, our study possessed certain strengths as well. In particular, this study was conducted in a population of HIV-infected persons with clinical follow-up and reliable information concerning antiretroviral use. The group studied was representative for two reasons: a large cohort of patients was evaluated and the profile of the patients within the group is similar to that of patients currently attending HIV clinics.

In conclusion, the risk of CKD in this large contemporary cohort of HIV-infected individuals appeared to be attributable to a combination of HIV-related risk factors. In addition to the traditional risk factors cited in the literature, both regimens containing tenofovir and HIV disease severity seem to be very important factors associated with CKD in patients with HIV.

Assessment of proteinuria constitutes a novel method for CKD staging in HIV-infected individuals and may be effectively used to stratify the risk of progression to ESRD. Given the increasing incidence of HIV-related renal diseases as a cause of ESRD and the increased mortality risk that ESRD imparts, further investigation of strategies to prevent or treat the renal complications of HIV infection is imperative.
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###### 

Demographic data comparing groups of pathological proteinuria and non-pathological proteinuria individuals.

  Factors                            N     Total (%)    Pathological Proteinuria Group   Non-Pathological Proteinuria Group   *p* value
  ---------------------------------- ----- ------------ -------------------------------- ------------------------------------ -----------
  **Population size**                      666 (100%)   133 (20.0)                       533 (80.0)                           \-
  **Age, years**                     666                                                                                      0.003
   18-39                                   288 (43.2)   42 (31.6)                        246 (46.2)                           
   \> 40                                   378 (56.0)   91 (68.4)                        287 (53.8)                           
  **Gender, male**                   666   343 (51.5)   62 (46.6)                        281 (52.7)                           0.245
  **Ethnicity**                      603                                                                                      
   Caucasian                               366 (60.7)   71 (57.7)                        295 (61.5)                           0.514
  **Abuse on drugs**                                                                                                          
   Alcohol                           635   92 (14.5)    26 (21.7)                        66 (12.8)                            0.019
   Tabaco                            634   249 (39.3)   54 (45.5)                        195 (37.9)                           0.159
   Crack cocaine                     635   24 (3.8)     6 (5.0)                          18 (3.5)                             0.431
   Inhaled cocaine                   634   21 (3.3)     2 (1.7)                          19 (3.7)                             0.396
   Cannabis                          634   19 (3.0)     4 (3.3)                          15 (2.9)                             0.769
  **Body mass index**                408                                                                                      
   Obese (≥ 30.0)                          56 (13.7)    12 (15.2)                        44 (13.4)                            0.811
  **Diabetes mellitus**              665   39 (5.9)     15 (11.3)                        24 (4.5)                             0.006
  **Dyslipidemia**                   665   174 (26.2)   35 (26.3)                        139 (26.1)                           1
  **Hypertension**                   659   142 (21.5)   36 (27.1)                        106 (20.2)                           0.106
  **Chronic hepatitis B**            666   20 (3.0)     7 (5.3)                          13 (2.4)                             0.094
  **Chronic hepatitis C**            664   80 (12.0)    29 (21.8)                        51 (9.6)                             \< 0.001
  **Current CD4 count, cells/mm3**   665                                                                                      0.001
   ≥500                                    313 (47.1)   47 (35.3)                        266 (50.0)                           
   200-500                                 282 (42.4)   62 (46.6)                        220 (41.4)                           
   \< 200                                  70 (10.5)    24 (18.0)                        46 (8.6)                             
  **HIV RNA, copies/mL**             666                                                                                      0.026
   \< 50                                   398 (59.8)   76 (57.1)                        322 (60.4)                           
   50-1,000                                110 (16.4)   15 (11.3)                        95 (17.8)                            
   \>1,000                                 158 (23.7)   42 (31.6)                        116 (21.8)                           
  **HAART regimen**                  651                                                                                      
   Yes                                     506 (77.7)   97 (76.4)                        409 (78.1)                           0.773
  **Current use of NRTI or NOT**     637                                                                                      \< 0.001
   TDF+3TC                                 175 (27.5)   52 (43.3)                        123 (23.8)                           
   AZT+3TC                                 317 (49.8)   38 (31.7)                        279 (54)                             
   NAIVE                                   145 (22.8)   30 (25)                          115 (22.2)                           
  **Based-therapy**                  666                                                                                      
  **NNRTI**                                                                                                                   
   Efavirenz                               197 (29.6)   37 (27.8)                        160 (30.0)                           0.696
   Nevirapine                              6 (0.9)      1 (0.8)                          5 (0.9)                              1
  **Protease inhibitors**                                                                                                     
   Lopinavir                               155 (23.3)   30 (22.6)                        125 (23.5)                           0.917
   Atazanavir                              126 (18.9)   27 (20.3)                        99 (18.6)                            0.741
   Fosamprenavir                           14 (2.1)     0 (0.0)                          14 (2.6)                             0.085
   Darunavir                               8 (1.2)      2 (1.5)                          6 (1.1)                              0.663

3TC: Lamivudine; AZT: Zidovudine; HAART: highly active antiretroviral therapy; NRTI: nucleoside reverse transcriptase inhibitors; NNRTI: Non- nucleoside reverse transcriptase inhibitors; TDF: Tenofovir.

###### 

Pathological proteinuria: Poisson regression model of all variables with *p*\<0.2 in the univariate analysis.

                                                  95%?Confidence Interval for PR   
  ------------------------------- ------- ------- -------------------------------- -------
  Age \>40 years                  0.323   1.242   0.808                            1.909
  Alcohol abuse                   0.342   1.271   0.775                            2.083
  Smoke                           0.433   1.178   0.782                            1.774
  Diabetes                        0.115   1.756   0.873                            3.494
  Hypertension                    0.244   1.323   0.826                            2.122
  Chronic Hepatitis B             0.264   1.631   0.691                            3.850
  Chronic Hepatitis C             0.117   1.488   0.905                            2.445
  Viral load \>1,000 copies/mL    0.059   1.543   0.973                            2.445
  Viral load 51-1,000 copies/mL   0.664   0.878   0.487                            1.583
  Viral load \<50 copies/mL               Ref                                      
  CD4 \<200 cells/mm^3^           0.031   1.947   1.062                            3.569
  CD4 500-200 cells/mm^3^         0.062   1.503   0.980                            2.305
  CD4 \>500 cells/mm^3^                   Ref                                      
  Regimen containing tenofovir    0.004   1.880   1.224                            2.887
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